(Q37103131)

18 August 2017

1 reference

title

Renal risk scores: progress and prospects (English)

1 reference

18 August 2017

M W Taal

1

1 reference

18 August 2017

B M Brenner

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

5 March 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

73

1 reference

18 August 2017

issue

11

1 reference

18 August 2017

page(s)

1216-1219

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.2008.36

18 August 2017

exact match

0 references

cites work

An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Risk of developing end-stage renal disease in a cohort of mass screening.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Predicting initiation and progression of chronic kidney disease: Developing renal risk scores

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Age affects outcomes in chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.36

7 January 2021

Identifiers

DOI

10.1038/KI.2008.36

1 reference

18 August 2017

1 reference